What are the contraindications for CGRP receptor antagonist (gepants) migraine medications such as rimegepant, ubrogepant, and atogepant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Contraindications for Gepant Migraine Medications

Gepants have only two absolute contraindications: concomitant use with strong CYP3A4 inhibitors and a history of serious hypersensitivity reactions to the specific gepant or its components. 1, 2

Absolute Contraindications

1. Strong CYP3A4 Inhibitors

  • Do not use gepants concurrently with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) 1
  • This applies to all gepants (ubrogepant, rimegepant, atogepant, zavegepant)
  • The mechanism: Strong CYP3A4 inhibitors dramatically increase gepant blood levels, raising toxicity risk

2. Serious Hypersensitivity History

  • Contraindicated in patients with prior serious hypersensitivity reactions to the specific gepant or any component 1, 2
  • Serious reactions include anaphylaxis and dyspnea
  • These reactions can occur within minutes, hours, or days after administration 1
  • If a serious hypersensitivity reaction occurs, discontinue immediately and initiate appropriate therapy

Important Clinical Considerations (Not Absolute Contraindications)

Pregnancy

  • Avoid gepants in pregnancy - the 2025 ACP guidelines specifically recommend these medications for "nonpregnant adults" 3, 4
  • Animal data suggests potential fetal harm 1
  • Discuss adverse effects during pregnancy and lactation with patients of childbearing potential 4

Severe Hepatic or Renal Impairment

  • Not contraindicated, but requires dose reduction to 50 mg for ubrogepant (maximum 100 mg per 24 hours) 1
  • Avoid use in end-stage renal disease 1

Drug Interactions Requiring Dose Adjustment (Not Contraindications)

  • Moderate or weak CYP3A4 inhibitors: Reduce dose
  • Strong CYP3A4 inducers: Should be avoided (will reduce gepant effectiveness) 1
  • BCRP and/or P-gp inhibitors: May require dose adjustment 1

Key Clinical Advantages

Gepants notably lack cardiovascular contraindications that limit triptan use, making them valuable alternatives for patients with cardiovascular disease, uncontrolled hypertension, or cerebrovascular disease 5, 6. They also appear unlikely to cause medication overuse headache given their preventive effects 5.

Common Pitfalls to Avoid

  • Do not confuse dose adjustments with contraindications - severe hepatic/renal impairment requires lower doses but is not an absolute contraindication
  • Check all concurrent medications for strong CYP3A4 inhibitors before prescribing
  • Screen for prior hypersensitivity to the specific gepant, as cross-reactivity between different gepants is not established
  • Remember pregnancy status - while not an FDA-labeled absolute contraindication, clinical guidelines clearly recommend avoiding use in pregnant patients 3, 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.